Quest Diagnostics Stock News

Let's see if Quest Diagnostics Incorporated (DGX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Let's see if Quest Diagnostics Incorporated (DGX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Quest Diagnostics (DGX) raises 2022 guidance based on the continued rebound in base business and recent investments expected to accelerate growth.

Quest Diagnostics (DGX) raises 2022 guidance based on the continued rebound in base business and recent investments expected to accelerate growth.

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP ( www.JohnsonFistel.com ) is investigating whether Quest Diagnostics Incorporated ("Quest" or the "Company") (NYSE: DGX ), any of its executive officers, or others violated federal securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. What actions may I take at this time? If you purchased Torrid securities and suffered significant losses on your investment, contact Johnson Fistel, LLP to submit your losses: Contact Lead Securities Analyst Jim Baker at [email protected] or (619) 814-4471 Click [ here ] or paste the following web address into your browser to join the investigation: https://www.cognitoforms.com/JohnsonFistel/QuestDiagnosticsIncorporated2 For more information, visit our website at Full story available on Benzinga.com

Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc. , Quest Diagnostics, Thermo Fisher Scientific Inc. , Pfizer, Bristol-Myers Squibb, Merck & Co. Inc. and Tepnel Pharma Services. Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc. , Quest Diagnostics, Thermo Fisher Scientific Inc. , Pfizer, Bristol-Myers Squibb, Merck & Co. Inc. and Tepnel Pharma Services.

Smart Beta ETF report for FXH

Monthly update of the Dividend Champions List. 139 companies declared higher dividends in the past month, with an average increase of 10.54% over their previous payouts.

UBS downgraded Quest Diagnostics stock to "neutral" from "buy"

UBS has downgraded Quest Diagnostics (DGX) from buy to neutral on fears the company wont be able to meet its own earnings target in 2023.

UBS said Quest''s 2023 earnings guidance may be too aggressive given the company''s rising costs.

Sector ETF report for FXH

Quest Diagnostics Inc (NYSE:DGX) stock is flat this morning, last seen 0.1% higher to trade at $130.71, after UBS downgraded the medical lab operator's shares to "neutral" from "buy.

Analysts have provided the following ratings for Quest Diagnostics (NYSE:DGX) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 7 0 0

Analysts have provided the following ratings for Quest Diagnostics (NYSE: DGX ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 7 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 3 0 0 2M Ago 0 0 2 0 0 3M Ago 0 1 1 0 0 In the last 3 months, 8 analysts have offered 12-month price targets for Quest Diagnostics. The company has an average price target of $151.62 with a high of $170.00 and a low of $129.00. Below is a summary of how these 8 analysts rated Quest Diagnostics over the … Full story available on Benzinga.com